Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

521589

registered interest
date	25/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will request that the Joint Committee on Vaccination and Immunisation undertakes an assessment of the recommendation from the Britain Against Cancer conference held in December 2015 to report its review on extending HPV vaccination to boys in 2016.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38503
answer	answer is ministerial correction date of answer 10/06/2016 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) advice needs to be based on a robust cost-effectiveness analysis. This is underway and Public Health England is due to report by early 2017. The JCVI has agreed that shortcuts could undermine the validity of the results and will begin its deliberations on extending vaccination to adolescent boys once all the necessary evidence is available. It is important that we follow a proper process and that the JCVI has a full understanding of the cost-effectiveness of vaccination programmes.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2016 10:54:05 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

521617

registered interest
date	25/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of whether the NHS Constitution's commitment to provide a comprehensive service available to all, irrespective of gender, is consistent with a policy of not providing an HPV vaccination programme for boys.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr John Baron
uin	38577
answer	answer is ministerial correction date of answer 06/06/2016 answer text <p>The NHS Constitution’s principle of a comprehensive service, available to all, does not mean that boys are automatically eligible to receive the human papillomavirus (HPV) vaccination because eligibility for the programme is based on expert advice. The Government is advised on immunisation matters by the independent expert committee, the Joint Committee on Vaccination and Immunisation (JCVI), which provides evidence-based advice.</p><p>The NHS Constitution states that people have the right to receive the vaccinations that the JCVI recommends that they should receive under an NHS-provided national immunisation programme. The JCVI has not yet recommended the introduction of an HPV vaccination programme for boys. It is currently considering this issue and its advice is expected in 2017.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 06/06/2016 14:19:33 answering member 3918 label Biography information for Jane Ellison
tabling member	1390 label Biography information for Mr John Baron

521263

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department holds information on the number of boys receiving HPV vaccinations through private provision.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38128
answer	answer is ministerial correction date of answer 02/06/2016 answer text <p>The Department does not hold information on the number of boys receiving human papillomavirus vaccinations through private provision.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 02/06/2016 15:39:45 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

521271

registered interest
date	24/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the timetable is for implementing HPV vaccinations at sexual health clinics for men who have sex with men.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	38133
answer	answer is ministerial correction date of answer 02/06/2016 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI), the expert body that advises the Government on all immunisation matters, advised that a targeted human papillomavirus (HPV) vaccination programme should be undertaken for men who have sex with men (MSM) up to 45 years of age who attend genitourinary medicine and HIV clinics. They noted that this should be subject to procurement of the vaccine and delivery of the programme at a cost-effective price. JCVI acknowledged that finding a way to implement its advice would be challenging and made clear that work was needed by the Department and others to consider commissioning and delivery routes for this programme.</p><p>The Department announced on 26 May 2016 that an HPV vaccination pilot for MSM would start in June.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 38132 question first answered 02/06/2016 15:24:39 answering member 3918 label Biography information for Jane Ellison
tabling member	1506 label Biography information for Andrew Gwynne

520545

registered interest
date	23/05/2016
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	CaTreasury
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord O’Neill of Gatley on 18 February (HL5912), when information about taxes paid by and benefits paid to EU migrants which was not available in February became available, and why that answer was not updated with the requested information.
tabling member printed	Lord Beecham
uin	HL183
answer	answer is ministerial correction date of answer 02/06/2016 answer text <p>The analysis on recently arrived non-UK EEA nationals subject to income tax and National Insurance contributions or receiving HMRC administered benefits became available on 12 May 2016 when it was published on HMRC’s publications page on GOV.UK.</p><p>No estimate of VAT paid by EU Nationals is held. VAT is levied on most goods and services, with the person’s nationality not generally recorded.</p> answering member printed Lord O'Neill of Gatley grouped question UIN HL186 question first answered 02/06/2016 13:05:16 answering member 4536 label Biography information for Lord O'Neill of Gatley
tabling member	4181 label Biography information for Lord Beecham

520546

registered interest
date	23/05/2016
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, in the light of the fact that the Sentencing Council’s fine calculator does not reflect the new victim surcharge fees for offences committed on or after 8 April, does not permit rounding for fines or victim surcharges, and allows fines to be imposed outside Magistrates’ Court Sentencing Guidelines, what steps they plan to take to make changes to the calculation method, and to confirm that the Ambay Software Sentencing Guidelines App complies fully with those guidelines.
tabling member printed	Lord Beecham
uin	HL184
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>The Sentencing Council has launched a new fines calculator, which is freely available on its website to assist magistrates when imposing fines. This takes account of the changes to the surcharge introduced on 8 April and enables calculations for multiple fines and rounding where appropriate<strong>. </strong>The calculator is a tool to assist sentencers and is not intended to replace the role of the court in determining the appropriate sentence in line with any relevant sentencing guidelines. Courts can only depart from sentencing guidelines if it is in the interests of justice to do so.</p> answering member printed Lord Faulks question first answered 07/06/2016 16:32:22 answering member 4183 label Biography information for Lord Faulks
tabling member	4181 label Biography information for Lord Beecham

519617

registered interest
date	19/05/2016
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Human Papillomavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they will include the current mobility criterion of 20 metres in the next review of Personal Independence Payments.
tabling member printed	Baroness Thomas of Winchester
uin	HL182
answer	answer is ministerial correction date of answer 27/05/2016 answer text <p>The terms of reference for the next Independent Review of Personal Independence Payment will be announced in due course.</p> answering member printed Baroness Altmann question first answered 27/05/2016 12:22:17 answering member 4533 label Biography information for Baroness Altmann
tabling member	3785 label Biography information for Baroness Thomas of Winchester

514044

registered interest
date	19/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, what assessment he has made of the implications for his Department's policies of the findings from the 2014 paper by Kavanagh and others, Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types; and whether such findings have been taken into account when assessing the differential impact of the bivalent and quadrivalent HPV vaccines on genital wart incidence.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	34693
answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department’s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department’s policies.</p><p>The answer of 23 March 2016 stated, ‘data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.’ This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.</p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 34694 34695 34696 question first answered 25/04/2016 14:55:51 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw

514045

registered interest
date	19/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether the time period referred to when providing details of the not anticipated reduction in genital warts associated with the bivalent vaccine takes into account the impact of the introduction of the quadrivalent vaccine in 2012.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	34694
answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department’s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department’s policies.</p><p>The answer of 23 March 2016 stated, ‘data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.’ This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.</p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 34693 34695 34696 question first answered 25/04/2016 14:55:51 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw

514075

registered interest
date	19/04/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 23 March 2016 to Question 31117, whether there has been any lasting duration of the HPV reduction that Public Health England have associated with the bivalent vaccine.
tabling member constituency	Exeter
tabling member printed	Mr Ben Bradshaw
uin	34695
answer	answer is ministerial correction date of answer 25/04/2016 answer text <p>The findings of Kavanagh and others, 2014, and of Mesher and others, 2016, are consistent with the reductions in human papillomavirus (HPV) 16/18 that were expected in the assessments that informed the Department’s policies. Neither of these papers report findings about genital warts incidence, both report no decrease in HPV types 6 and 11; this is also consistent with expectations in assessments that informed the Department’s policies.</p><p>The answer of 23 March 2016 stated, ‘data reported to Public Health England (PHE) from genitourinary medicine (GUM) clinics shows a reduction in rates of genital warts diagnoses at GUM clinics between 2009 and 2014.’ This analysis has been updated with data for 2013 and 2014. The reductions reported were in patients aged 15 years and older. As the introduction of the quadrivalent vaccine was in 2012, to 12 year olds, no impact on genital warts in 15+ year olds within this time period was expected due to this introduction. Use of the quadrivalent vaccine within this age group prior to its introduction in the national immunisation programme was assessed as a possible but highly unlikely cause of the reductions seen.</p><p>The latest data from PHE showing reductions in genital warts diagnoses in GUM clinics amongst ages offered the bivalent vaccine are data for 2014: the future duration of any protection from genital warts associated with the bivalent vaccine has not been (and cannot be) inferred.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 34693 34694 34696 question first answered 25/04/2016 14:55:51 answering member 3918 label Biography information for Jane Ellison
tabling member	230 label Biography information for Mr Ben Bradshaw